CLINICAL PIPELINE

VAX014 is being investigated for safety, tolerability, and efficacy following intratumoral administration in patients with advanced solid tumors in a multi-center Phase 1 clinical trial. The dose escalation component of the trial is nearly complete after which an expansion phase will be initiated in combination with systemic immune checkpoint blockade.

VAX014 has previously been investigated for the topical intravesical treatment of non-muscle invasive bladder cancer in a Phase 1 study in patients with low grade papillary (TaG1) NMIBC. This study is now closed, but demonstrated a good safety profile and antitumor activity. Future studies in NMIBC and other genitourinary cancers are part of the long term plan for VAX014.